Research programme: lung disorder therapeutics - Lung Therapeutics/University of Texas Health Sciences Center at Tyler

Drug Profile

Research programme: lung disorder therapeutics - Lung Therapeutics/University of Texas Health Sciences Center at Tyler

Alternative Names: LTI-01; LTI-02; LTI-03; scuPA; Single chain urokinase plasminogen activator

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator Lung Therapeutics; University of Texas at Tyler
  • Class Plasminogen activator enzymes; Serine endopeptidases
  • Mechanism of Action Fibrinolytic agents; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Empyema
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lung injury; Pleural effusion
  • Research Idiopathic pulmonary fibrosis

Most Recent Events

  • 13 Jan 2015 LT 01 receives Orphan Drug status for Empyema in European Union
  • 02 Dec 2014 LTI 01 receives Orphan Drug status for Empyema in USA
  • 28 Oct 2014 Early research in Idiopathic pulmonary fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top